MediWound Ltd. (MDWD) News
Follow MediWound Ltd. (MDWD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
MediWound Prices $17.25 Million Share Offering at $12.50 Per Share
MediWound Prices $17.25 Million Share Offering at $12.50 Per Share MediWound priced a follow-on
EQUITY | Nov 05, 2026, 04:28 PM UTC
M
MediWound Announces $15 Million Bought Deal Offering
EQUITY | Nov 03, 2026, 09:47 PM UTC
M
MediWound to Report Third-Quarter 2026 Results
MediWound says it will report its third-quarter 2026 financial results.
EQUITY | Oct 29, 2026, 12:00 PM UTC
L
Weekly Recap: DoD funding for NexoBrid and VALUE Phase III reassessment
MediWound Ltd. (NASDAQ:MDWD) secured $3.3M in non-dilutive DoD funding to bring a room-temperature NexoBrid formulation toward IND readiness while advancing a global Phase III VALUE trial of EscharEx for venous leg ulcer
NEWS | Sep 28, 2026, 11:03 AM UTC
H
MediWound Announces Additional $3.3M In Department Of War Funding To Develop Room-Temperature-Stable NexoBrid For Battlefield Burn Care
MediWound Announces Additional $3.3M In Department Of War Funding To Develop Room-Temperature-Stable NexoBrid For Battlefield Burn Care
LIVE | Sep 22, 2026, 11:06 AM UTC
H
MDWD - MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MDWD - MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
GEOPOLITICS | Sep 22, 2026, 11:02 AM UTC
L
MDWD: Phase III VALUE trial and manufacturing expansion drive growth, with strong competitive positioning
Key growth drivers include the phase III VALUE trial for EscharEx, ongoing expansion of manufacturing capacity, and steady revenue from NexoBrid. Competitive positioning is strong, with faster debridement than legacy pro
NEWS | Sep 14, 2026, 07:28 PM UTC
L
MDWD: VALUE phase III trial and manufacturing expansion set the stage for growth in wound care
A validated enzymatic platform drives growth, with NexoBrid generating revenue and EscharEx in a pivotal phase III trial for chronic wounds. The main catalyst is the VALUE trial readout by Q1 2027, while manufacturing ex
EARNINGS | Sep 14, 2026, 07:04 PM UTC
L
MediWound CEO Ofer Gonen to present at H.C. Wainwright conference
MediWound said CEO Ofer Gonen will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 2, 2026.
GEOPOLITICS | Sep 02, 2026, 11:07 AM UTC
L
MDWD - MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MDWD - MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 02, 2026, 11:02 AM UTC
L
MediWound reports Q2 revenue decline, reaffirms 2026 guidance
MediWound said Q2 2026 revenue fell to $3.1 million from $5.7 million a year earlier, while it reaffirmed full-year 2026 revenue guidance of $24 million to $26 million.
EARNINGS | Aug 13, 2026, 01:43 PM UTC
L
MediWound affirms FY2026 sales guidance at $24.0M–$26.0M
MediWound (MDWD) affirms FY2026 sales outlook at $24.000M–$26.000M, versus a $24.125M estimate.
EARNINGS | Aug 13, 2026, 11:00 AM UTC
L
MediWound (MDWD) reports Q2 2026 financial results and corporate update
MediWound (MDWD) reports its second quarter 2026 financial results and provides a corporate update, with no figures or guidance details included in the feed.
EARNINGS | Aug 13, 2026, 11:00 AM UTC
L
MDWD - MediWound to Report Second Quarter 2026 Financial Results
MDWD - MediWound to Report Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 12:00 PM UTC